Advertisement

Doctors and researchers go back and forth on how to proceed with renal denervation studies since medtech titan Medtronic's bellwether trial fell short.

Medtech titan Medtronic (NYSE:MDT) rocked the renal denervation world when it reported earlier this month that it's bellwether Symplicity clinical trial failed to meet efficacy expectations when compared to a sham control arm.

Physicians and researchers are trying to pick up the pieces and determine what the results mean for renal denervation technology, which had gained significant prominence as a potential game-changer for hypertension treatment.

Advertisement
Advertisement